About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
S
ASH 2023 Insights: "iStopMM Study - Risk Factors of Smoldering Multiple Myeloma"
By
Insights from 2023 ASH Annual Meeting
FEATURING
Sigrun Thorsteinsdottir
By
Insights from 2023 ASH Annual Meeting
FEATURING
Sigrun Thorsteinsdottir
0 views
December 14, 2023
Comments
0
Login to view comments.
Click here to Login
Featured Video
24:35
Indy Hematology Review
Current Approaches in the Treatment of Myeloproliferative Neoplasms
Feat.
A. Tefferi
Featured Video
16:26
Incyte
Effects of a Treatment Option on Hematocrit Control and Spleen Volum…
Feat.
C. Harrison
Recommended
AUTOPLAY
ON
Related
Newest
19:08
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGU…
Feat.
R. Banerjee
32:06
Scripps Health
Should Patients With High-Risk SMM Be Treated Outside a Clinical Tri…
Feat.
M. Gertz
35:27
Dana-Farber Cancer Institute
Advances in Multiple Myeloma 2024: From Bench to Bedside
Feat.
K. Anderson
28:20
PleXus Communications
Why We Should Not Treat SMM
Feat.
B. Derman
04:15
Indy Hematology Review
Indy Hematology Review 2023: Plasma Cell Neoplasms and Amyloidosis U…
Feat.
M. Gertz
11:55
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "CENTAURUS Study Final Analysis - Efficacy &…
Feat.
O. Landgren
32:03
Indy Hematology Review
Emerging and Current Treatment of MM: What Should We Know and What S…
Feat.
K. Anderson
52:39
Yale Cancer Center
Myeloma in 2023: So Many Drugs, Yet So Few Cures
Feat.
A. Chari
22:15
5th SOHO Italy Annual Conference
SOHO Italy 2023: Multiple Myeloma Cured in 2030 - What Are the Next …
Feat.
K. Anderson
19:35
Dana-Farber Cancer Institute
Updates in the Management of SMM/MGUS and the Prevention of Progress…
Feat.
Y. Liu
08:35
GRACE
Oncologists' Guidance on Treating Smoldering Myeloma: Panel Dis…
Feat.
A. Goodman,
A. Taneja,
T. Phillips
13:51
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 DEBATE: Smoldering MM - Time to Watch and Wait
Feat.
A. Dispenzieri
21:16
UChicago Medicine
Myeloma 2022: Challenges and Path Forward
Feat.
A. Jakubowiak
10:09
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Next Questions for MM in the Coming 5-10 Years
Feat.
T. Martin
10:25
5th SOHO Italy Annual Conference
SOHO Italy 2023: Is It Time for a Biomarkers-Driven Approach in Smol…
Feat.
I. Ghobrial
32:49
PleXus Communications
Myeloma Rounds: Asymptomatic Patient With High-Risk SMM
Feat.
N. Antao,
P. Hagen
07:20
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Daratumumab, Bortezomib, Lenalidomide, and …
Feat.
O. Nadeem
10:36
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Immuno-PRISM Study of Bispecific Antibodies…
Feat.
O. Nadeem
14:03
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 DEBATE: Smoldering MM - Personalized Time to Treat?
Feat.
S. Lonial
14:52
5th SOHO Italy Annual Conference
SOHO Italy 2023: MM State-of-the-Art in the USA and Evolving Questio…
Feat.
H. Lee
